Carna Biosciences, Inc. (TYO:4572)
Japan
· Delayed Price · Currency is JPY 312.00
-23.00 (-6.87%)
Jun 19, 2025, 3:30 PM JST
Carna Biosciences Revenue
Carna Biosciences had revenue of 143.35M JPY in the quarter ending March 31, 2025, a decrease of -20.36%. This brings the company's revenue in the last twelve months to 598.71M, down -62.08% year-over-year. In the year 2024, Carna Biosciences had annual revenue of 636.00M, down -60.86%.
Revenue (ttm)
598.71M
Revenue Growth
-62.08%
P/S Ratio
10.69
Revenue / Employee
9.50M
Employees
63
Market Cap
6.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 636.00M | -989.00M | -60.86% |
| Dec 31, 2023 | 1.63B | 239.00M | 17.24% |
| Dec 31, 2022 | 1.39B | -631.00M | -31.28% |
| Dec 31, 2021 | 2.02B | 884.00M | 78.02% |
| Dec 31, 2020 | 1.13B | -2.07B | -64.67% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Takeda Pharmaceutical Company | 4,581.55B |
| Daiichi Sankyo Company | 1,886.26B |
| HOYA Corporation | 869.37B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 997.33B |